Nouscom raises EUR120M Series C+ backed by 15 investors
The round closed on October 1, 2026, with participation from 5AM Ventures, Andera Partners, Angelini Ventures, Aurea, Bpifrance, CDP Venture Capital, EQT Ventures, Indaco Venture Partners, M Ventures, NEVA SGR, Panakes Partners, Revelation Partners, Versant Ventures, and XGEN Venture. The company has raised nearly half a billion euros to date across eight rounds.
Nouscom develops next-generation, off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens for prevention and treatment. The company is headquartered in Switzerland and operates in the Healthcare & Life Sciences sector at the series-c-plus stage. It was co-founded by Jeremy Lewis and Christoph Hoos.
Brouky tracks 79 deals in Healthcare & Life Sciences in Switzerland over the past 12 months, with a median deal size of EUR10.3M.
Related insights
- Deal SpotlightPigment raises EUR223M in Series C+ with EQT Ventures, GS Growth and others participating
- Deal SpotlightMOSI raises EUR130M Pre Seed backed by nine investors
- Deal SpotlightYazen raises EUR50000000 Series C+ backed by Verdane Capital
- Deal SpotlightTrustly raises EUR34.8M Series B backed by Alfvén & Didrikson and Nordic Capital
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.